Cargando…
Health technology assessment and price negotiation alignment for rare disorder drugs in Canada: Who benefits?
BACKGROUND: Since 2014, the Canadian Agency for Drugs and Technologies in Health (CADTH), which performs health technology assessments for all federal, provincial and territorial government drug programs (except Quebec’s) and the pan-Canadian Pharmaceutical Alliance (pCPA), which conducts price nego...
Autor principal: | Rawson, Nigel S. B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9190095/ https://www.ncbi.nlm.nih.gov/pubmed/35698235 http://dx.doi.org/10.1186/s13023-022-02390-x |
Ejemplares similares
-
Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost
por: Rawson, Nigel S. B.
Publicado: (2017) -
Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016) -
Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022) -
Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022) -
Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
por: Jenei, Kristina, et al.
Publicado: (2023)